S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Price, News & Analysis

$23.74
+0.50 (+2.15%)
(As of 03/4/2024 ET)
Today's Range
$22.71
$23.77
50-Day Range
$22.56
$30.27
52-Week Range
$22.50
$44.09
Volume
273,898 shs
Average Volume
276,239 shs
Market Capitalization
$706.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.50

Fulgent Genetics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
32.7% Upside
$31.50 Price Target
Short Interest
Healthy
2.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.56mentions of Fulgent Genetics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$583,440 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.81) to ($1.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.39 out of 5 stars

Medical Sector

126th out of 960 stocks

Medical Laboratories Industry

6th out of 21 stocks


FLGT stock logo

About Fulgent Genetics Stock (NASDAQ:FLGT)

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

FLGT Stock Price History

FLGT Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q4 2023 Fulgent Genetics Inc Earnings Call
Here's what to expect from Fulgent Genetics's earnings report
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
FLGT Mar 2024 30.000 call
FLGT Mar 2024 35.000 put
Following Up On Fulgent Genetics
Q3 2023 Fulgent Genetics Inc Earnings Call
Fulgent Genetics Reports Loss In Q3 On Lower Revenue
Fulgent Reports Third Quarter 2023 Financial Results
See More Headlines
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
3/05/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:FLGT
Employees
1,184
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$31.50
High Stock Price Target
$35.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+32.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-167,820,000.00
Pretax Margin
-60.19%

Debt

Sales & Book Value

Annual Sales
$289.21 million
Cash Flow
$3.32 per share
Book Value
$38.24 per share

Miscellaneous

Free Float
20,325,000
Market Cap
$706.98 million
Optionable
Optionable
Beta
1.45

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives















FLGT Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FLGT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View FLGT analyst ratings
or view top-rated stocks.

What is Fulgent Genetics' stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for Fulgent Genetics' stock. Their FLGT share price targets range from $28.00 to $35.00. On average, they expect the company's stock price to reach $31.50 in the next year. This suggests a possible upside of 32.7% from the stock's current price.
View analysts price targets for FLGT
or view top-rated stocks among Wall Street analysts.

How have FLGT shares performed in 2024?

Fulgent Genetics' stock was trading at $28.91 on January 1st, 2024. Since then, FLGT stock has decreased by 17.9% and is now trading at $23.74.
View the best growth stocks for 2024 here
.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a increase in short interest in February. As of February 15th, there was short interest totaling 517,200 shares, an increase of 10.1% from the January 31st total of 469,900 shares. Based on an average trading volume of 194,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 2.7% of the company's stock are short sold.
View Fulgent Genetics' Short Interest
.

When is Fulgent Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our FLGT earnings forecast
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its quarterly earnings results on Friday, November, 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.07. The company had revenue of $84.70 million for the quarter, compared to the consensus estimate of $64.42 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 3.04% and a negative net margin of 58.03%. The business's quarterly revenue was down 19.9% on a year-over-year basis. During the same quarter last year, the company posted $0.11 earnings per share.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of -1.050--1.050 for the period, compared to the consensus earnings per share estimate of -0.950. The company issued revenue guidance of $280.0 million-$280.0 million, compared to the consensus revenue estimate of $294.2 million.

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.88%), Vanguard Group Inc. (4.78%), Park West Asset Management LLC (1.43%), Nuveen Asset Management LLC (0.93%), Charles Schwab Investment Management Inc. (0.90%) and Northern Trust Corp (0.78%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends
.

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Fulgent Genetics have any subsidiaries?
The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
This page (NASDAQ:FLGT) was last updated on 3/5/2024 by MarketBeat.com Staff